Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
A bulk drug substance is an active pharmaceutical ingredient intended to be incorporated into a finished drug product and to provide pharmacological activity or another direct effect
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
This information provides significant reassurance for numerous users
This was the first year ICD-10-CM was implemented into the HIPAA code set
Sarris, J., Kean, J., Schweitzer, I., and Lake, J
The Promise of New Weight Loss Solutions These new medications offer real hope for weight loss
US$ 25.34
US$ 20.96
US$ 29.84
